KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EPS (Weighted Average and Diluted) (2019 - 2026)

GoodRx Holdings' EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at $0.02 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed 0.0% to $0.02 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.09, a 80.0% increase, with the full-year FY2025 number at $0.09, up 125.0% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.02 in Q4 2025 for GoodRx Holdings, up from $0.0 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for GDRX hit a ceiling of $0.14 in Q2 2023 and a floor of -$0.1 in Q3 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.0 across 5 years, with a median of $0.0 in 2025.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 4177.66% in 2023, down 500.0% in 2023.
  • Tracing GDRX's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.09 in 2021, then surged by 88.89% to -$0.01 in 2022, then crashed by 500.0% to -$0.06 in 2023, then surged by 133.33% to $0.02 in 2024, then dropped by 0.0% to $0.02 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for GDRX at $0.02 in Q4 2025, $0.0 in Q3 2025, and $0.04 in Q2 2025.